
    
      This is a randomized (1:1) double-masked, vehicle-controlled, multi-center, parallel group
      study with two treatment arms: NVC-422 Ophthalmic Solution 0.33% ("NVC-422") and NVC-422
      Vehicle ("Vehicle").

      Subjects that meet all inclusion/exclusion criteria will be enrolled into the study,
      randomized and evaluated at 6 visits:

        -  Visit 1: Screening, Day 1

        -  Visit 2: Day 3

        -  Visit 3: Day 6

        -  Visit 4: Day 11 End of Treatment (EOT)

        -  Visit 5: Day 18 Test-of-Cure (TOC)

        -  Visit 6: Day 42 Follow-up

      Subjects were dosed OU for 10 days. Specimens were collected OU at each visit for
      quantitative PCR adenoviral load and molecular typing.
    
  